Edoxaban

Aka: Edoxaban, Savaysa

advertisement

II. Mechanism

  1. Factor Xa Inhibitor

III. Indications

  1. Atrial Fibrillation Anticoagulation
  2. Deep Vein Thrombosis
    1. However, must be started concurrently with Heparin, unlike other Factor Xa Inhibitors (Apixaban, Rivaroxaban)

IV. Contraindications

  1. Creatinine Clearance <15 ml/min/1.73m2
  2. Creatinine Clearance >95 ml/min/1.73m2 (lower efficacy due to high drug clearance)
  3. Severe Cirrhosis (Child-Pugh Class C)

V. Dosing

  1. Standard dose: 60 mg orally daily
  2. Half dose indications (30 mg orally daily)
    1. Creatinine Clearance 15 to 50 ml/min/1.73m2 OR
    2. Weight <60 kg

VI. Pharmacokinetics

  1. Oral bioavailability: 62%
  2. Half-life: 10-14 hours
  3. Onset: 1-2 hours
  4. Renal clearance 50%

VII. References

  1. Steinberg (2014) BMJ 348: g2116 +PMID:24733535 [PubMed]
  2. Wilbur (2017) Am Fam Physician 95(5): 295-302 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Edoxaban." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies (from Trip Database) Open in New Window

Cost: Medications

savaysa (on 4/19/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
SAVAYSA 30 MG TABLET $10.17 each
SAVAYSA 60 MG TABLET $10.10 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

Ontology: edoxaban (C2975435)

Definition (NCI) An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion.
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C552171
English edoxaban, Edoxaban, Ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-, N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide, EDOXABAN
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

advertisement

2019 Family Practice Notebook, LLC. Terms | Privacy (EHS) | About | Site Map | Blog

Footer Site Logo